Issue of Equity

RNS Number : 6328Z

IXICO plc

13 January 2020

 

13 January 2020

IXICO plc

("IXICO" or the "Company")

 Issue of Equity

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 188,998 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options.

The New Shares are expected to be admitted to trading on AIM on 15 January 2020.

Total voting rights

Application has been made for admission to trading on AIM of 188,998 New Shares.  Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 15 January 2020, following which there will be in total 47,091,292 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)	[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications	[phone]
Mary Clark / Supriya Mathur / Manuel Mateus
[e-mail]

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.

Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

 

END

 

 

IOEFLFFVLDIVLII